Researchers Discover 10 New Immune Systems in Bacteria. Get Updates on the Global Action Plan on AMR at the Event in London.

Lonodon, United Kingdom, February 05, 2018 --(PR.com)-- SMi's Superbugs & Superdrugs Conference 19 - 20 March, London, UK

Bacteria have been defending themselves from phages—viruses that attack bacterial cells—for billions of years, and, unlocking the immune mechanisms they use to protect themselves has led to the development of powerful molecular biology tools such as restriction enzymes and CRISPR-Cas9. Now, researchers report in Science (January 25) that they have discovered 10 more immune systems that bacteria use to protect themselves against phages and plasmids, opening up the possibility to add new tools to the molecular biology toolbox.* “Whenever a complex immune system is discovered and its mechanism is eventually understood, it can become a very effective tool. Immune systems must be highly selective in identifying specific molecules in order to function well. In molecular biology, this is exactly what we need.”**

This discovery could have a huge impact on AMR as it opens up new opportunities, but also brings new challenges.

Taking place in London on 19 - 20th March, the theme for the SMi's Superbugs & Superdrugs Conference is to tackle the scientific, regulatory and economic challenges to combat AMR. Hear exclusive case studies on clinical progress and evaluate the latest incentives and funding solutions to build your antibiotic pipeline.

Plus - 21 March - Don’t miss post conference workshop for interactive training on the use of animal models in pre-clinical drug development hosted by University of North Texas Health Science Centre

Don't forget to check out the latest agenda, line-up and attendee list by visiting www.superbugssuperdrugs.com/prcom

Christopher Houchens’ (BARDA) presentation from the last year’s Superbugs & Superdrugs Conference is available online with information on BARDA’s Mission, Funding Antibacterial Development, National Strategy and Action Plan for CARB, Insufficient Pipeline, Industry Disengagement, BARDA’s Goal, Strategy and Priorities, WHO AMR Priorities, Portfolio Partnerships, What to Expect from CARB-X.

Visit event Download Centre to view this presentation www.superbugssuperdrugs.com/prcom

Hear current updates on the above from Mark Albrecht, Health Scientist, HHS/ASPR/BARDA who will be presenting at the Superbugs & Superdrugs Conference this March.

Also available exclusive interviews with:
- Domingo Gargallo-Viola, CSO at ABAC Therapeutics
- David Brown, Managing Director and Founder, Alchemy Biomedical Consulting
- John George, Founder and CSO, Oppilotech

LinkedIn – search "SMi Pharma"
Twitter – we are @SMIpharm and #smibugs

Superbugs & Superdrugs Confernce | 19 - 20 March 2018 | London, UK

* By Jim Daley | January 25, 2018, The Scientist
** Rotem Sorek, a molecular geneticist at the Weizmann Institute of Science in Israel